RxDoctor Payments Data

Neil Smerling, MD

Internal Medicine · North Port, FLNPI 1154367522

Payments from drug & device makers

$9,780in general payments, 2019–2025

Across 438 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$902
  • AbbVie$575
  • Corcept Therapeutics$475
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,766100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,780 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$123,881
Medicare patients
270
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$146,300
OzempicSemaglutide102$143,541
EliquisApixaban86$127,505
JardianceEmpagliflozin78$94,524
FarxigaDapagliflozin Propanediol79$85,120
TrulicityDulaglutide43$63,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$41,212
XareltoRivaroxaban29$35,602
EntrestoSacubitril/Valsartan16$18,179
MyrbetriqMirabegron11$14,222
JanuviaSitagliptin Phosphate24$14,107
LinzessLinaclotide13$12,581
Rosuvastatin Calcium456$3,124
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,056
Metoprolol Succinate221$3,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,003$210,104160 claims
Novo NordiskOzempic$1,248$143,541102 claims
PfizerEliquis$409$127,50586 claims
Boehringer IngelheimJardiance$349$94,52478 claims
AstraZenecaFarxiga$1,603$85,12079 claims
GSKTrelegy Ellipta$413$41,21235 claims
Johnson & JohnsonXarelto$112$35,60229 claims
NovartisEntresto$432$18,17916 claims
AbbVieLinzess, Synthroid$575$15,12138 claims
Astellas Pharma US IncMyrbetriq$46$14,22211 claims
MerckJanuvia$104$14,10724 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,535285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in North Port

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →